尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察

摘要

Objective:To investigate the efficacy and toxicity of Nimotuzumab combined with concurrent radiother-apy and chemotherapy in treatment of advanced esophageal cancer.Methods:All 46 cases of advanced esophageal cancer using Nimotuzumab combined radiotherapy and chemotherapy were compared with the same number of ra-diotherapy and chemotherapy group.Results:The complete remission and total response rate of combined group was 47.8% and 87.0%,higher than the control group's 43.5% and 84.8%.No significant increase in actue adverse re-actions,Nimotuzumab showed a low incidence of side effects.Conclusion:The treatment of combined Nimotuzumab with radiotherapy and chemotherapy for advanced esophageal has a better curative effect and no significant increase in toxicity.%目的：观察尼妥珠单抗联合同步三维适形放疗、化疗治疗中晚期食管癌的近期疗效及不良反应。方法：46例中晚期食管癌采用尼妥珠单抗联合放、化疗与同数量单纯放、化疗组对比，观察治疗不良反应并评价近期疗效。结果：联合治疗组完全缓解率、有效率分别为47．8％、87．0％，较对照组的43．5％、84．8％有提高。急性不良反应发生率未见显著升高，与应用尼妥珠单抗产生的相关不良反应发生率较低。结论：尼妥珠单抗联合同步三维适形放、化疗治疗中晚期食管癌近期疗效较好，不良反应未见明显增加。